SCHEMBL16742902

SCHEMBL16742902

CC(=O)Oc1ccc(C)nc1C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54
KDM4E B2RXH2 5/20 0.43
TSHR P16473 4/20 0.43
ALDH1A1 P00352 3/20 0.43
RAB9A P51151 2/20 0.43
GAA P10253 1/20 0.43
CFD P00746 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
LMNA P02545 1/20 0.41
TDP1 Q9NUW8 2/20 0.40
ESR1 P03372 1/20 0.40
ITGB3 P05106 1/20 0.40
ITGA2B P08514 1/20 0.40
HMGB1 P09429 1/20 0.40
HPGD P15428 1/20 0.40
GGT1 P19440 1/20 0.40
PTGS1 P23219 1/20 0.40
PTGS2 P35354 1/20 0.40
BLM P54132 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9413721 0.84 MEN1 (0.54) MEN1KMT2AKDM4ETSHRALDH1A1
SCHEMBL9413725 0.82 KMT2A (0.53) MEN1KMT2AKDM4EALDH1A1GAA
SCHEMBL27703249 0.81 CFD (0.43) MEN1KMT2AKDM4ETSHRALDH1A1
SCHEMBL27850348 0.81 CFD (0.44) MEN1KMT2AKDM4ETSHRALDH1A1
SCHEMBL2829068 0.81 GABRP (0.50) MEN1KMT2AKDM4ETSHRALDH1A1
SCHEMBL1128204 0.81 KDM4E (0.43) MEN1KMT2AKDM4ETSHRALDH1A1
SCHEMBL16742712 0.79 KDM4E (0.56) MEN1KMT2AKDM4ETSHRALDH1A1
SCHEMBL28743052 0.77 KMT2A (0.50) MEN1KMT2ATSHRGAAL3MBTL1
SCHEMBL1128526 0.77 GPR119 (0.43) KMT2AKDM4ETSHRALDH1A1RAB9A
SCHEMBL27831725 0.77 PTGS1 (0.40) MEN1KMT2AKDM4ETSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023220439-A1 COMPOSITIONS USEFUL FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. (US) 2023-11-16 WO disclosed
US-9765092-B2 Tricyclic piperidine compounds ACTELION PHARMACEUTICALS LTD (CH) 2017-09-19 US disclosed
EP-3071578-A1 TRICYCLIC PIPERIDINE COMPOUNDS Actelion Pharmaceuticals Ltd (CH) 2016-09-28 EP disclosed
US-20160272655-A1 TRICYCLIC PIPERIDINE COMPOUNDS ACTELION PHARMACEUTICALS LTD (CH) 2016-09-22 US disclosed
WO-2015075023-A1 TRICYCLIC PIPERIDINE COMPOUNDS ACTELION PHARMACEUTICALS LTD (CH) 2015-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160272655-A1 TRICYCLIC PIPERIDINE COMPOUNDS TPH1, HTR1B, HTR1A MEN1 1689/4885KMT2A 579/4885KDM4E 1327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.